1. Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer
   Heng Liang et al, 2024, MedComm CrossRef
2. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor
   Xiaotian Song et al, 2021, Frontiers in Immunology CrossRef
3. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity
   Theodoros Eleftheriadis et al, 2020, Archivum Immunologiae et Therapiae Experimentalis CrossRef
4. Inhibition of acetyl‑CoA carboxylase by PP‑7a exerts beneficial effects on metabolic dysregulation in a mouse model of diet‑induced obesity
   Tianya Liu et al, 2020, Experimental and Therapeutic Medicine CrossRef
5. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
   Adaobi Amobi-McCloud et al, 2021, Frontiers in Immunology CrossRef
6. Metabolomic Disparities in Intraocular Fluid Across Varied Stages of Cataract Progression: Implications for the Analysis of Cataract Development
   Arturs Zemitis et al, 2024, Journal of Ocular Pharmacology and Therapeutics CrossRef
7. The effect of lipid metabolism disorder on patients with hyperuricemia using Multi-Omics analysis
   Lili Ma et al, 2023, Scientific Reports CrossRef
8. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
   Theodoros Eleftheriadis, 2018, Frontiers in Immunology CrossRef